High PD-L1 expression as a negative prognostic factor in stage III but not in stage II gastric cancer

Table 1 Baseline patient characteristics

Variables	Cases	Total
Sex		388
Male	249 (64.2)
Female	139 (35.8)
Age (year)	58.05 ± 12.61
Tumor size (cm)		387
< 5	266 (68.7)
≥ 5	121 (31.3)
Lesion sites		386
Stomach	294 (76.2)
GEJ	92 (23.8)
Histology		385
Sig	141 (36.6)
Others	244 (63.4)
Grade		381
G1-G2	80 (21.0)
G3	301 (79.0)
Pathological stage		388
pII	159 (41.0)
pIIIA	99 (25.5)
pIIIB	84 (21.6)
pIIIC	46 (11.9)
Postoperative adjuvant chemotherapy		388
Yes	229 (59.0)
No	159 (41.0)
HER-2 expression		369
Negative	337 (91.3)
Positive	32 (8.7)
MMR status		368
dMMR	20 (5.4)
pMMR	348 (94.6)
EBV status		376
Negative	360 (95.7)
Positive	16 (4.3)
PD-L1 CPS		388
Negative (< 1)	126 (32.5)
Positive (≥ 1)	262 (67.5)
pII		159
Negative (< 1)	52 (32.7)
Positive (≥ 1)	107 (67.3)
pIII		229
Negative (< 1)	74 (32.3)
Positive (≥ 1)	155 (67.7)
PD-L1 CPS		388
Low expression (< 5)	187 (48.2)
High expression (≥ 5)	201 (51.8)
pII		159
Low expression (< 5)	74 (46.5)
High expression (≥ 5)	85 (53.5)
pIII		229
Low expression (< 5)	113 (49.3)
High expression (≥ 5)	116 (50.7)
Ki-67 index	59.31 ± 23.04

Data were shown as n (%) or mean ± SD. GEJ: Gastroesophageal junction; Sig: Signet ring cell carcinoma; pII: Pathological stage II; pIII: Pathological stage III; MMR: Mismatch repair; dMMR: Deficient mismatch repair; pMMR: Proficient mismatch repair; EBV: Epstein-Barr virus; PD-L1: Programmed death ligand-1; CPS: Combined positive score.